<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01897441</url>
  </required_header>
  <id_info>
    <org_study_id>13-02-079</org_study_id>
    <secondary_id>NCI-2013-01194</secondary_id>
    <secondary_id>13-02-079</secondary_id>
    <secondary_id>P30CA013330</secondary_id>
    <nct_id>NCT01897441</nct_id>
  </id_info>
  <brief_title>Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer</brief_title>
  <official_title>Prospective Tissue Collection in Breast Cancer Patients Receiving Preoperative Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized pilot clinical trial studies chemotherapy before surgery and tissue sample
      collection in patients with stage IIA-IIIC breast cancer. Drugs used in chemotherapy, such as
      doxorubicin hydrochloride, cyclophosphamide, and paclitaxel, work in different ways to stop
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.
      Monoclonal antibodies, such as trastuzumab, may interfere with the ability of tumor cells o
      grow and spread. Giving doxorubicin hydrochloride, cyclophosphamide, paclitaxel and
      trastuzumab may kill more tumor cells. Collecting and storing samples of tissue from patients
      with breast cancer to study in the laboratory may help doctors learn more about how well
      patients will respond to treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the effects of preoperative neoadjuvant paclitaxel and doxorubicin
      (doxorubicin hydrochloride)/cyclophosphamide (AC) on: senescence; invasion/motility (tumor
      microenvironment of metastasis [TMEM] and 67 kDa laminin receptor [67LR]).

      II. To create a biospecimen repository for future studies derived from patients with breast
      cancer receiving standard neoadjuvant chemotherapy.

      OUTLINE: Patients with human epidermal growth factor receptor 2 (HER2)-positive disease are
      assigned to Stratum A, and patients with HER2-negative disease are randomized to Stratum B or
      C.

      STRATUM A: Patients receive paclitaxel intravenously (IV) over 1 hour and trastuzumab IV over
      30-90 minutes weekly for 12 weeks. Beginning 2-3 weeks later, patients receive doxorubicin
      hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes every 2 weeks
      for 8 weeks

      STRATUM B: Patients receive paclitaxel, doxorubicin hydrochloride, and cyclophosphamide as in
      Stratum A.

      STRATUM C: Patients receive doxorubicin hydrochloride IV over 5-10 minutes and
      cyclophosphamide IV over 30-60 minutes every 2 weeks for 8 weeks. Patients then receive
      paclitaxel IV over 1 hour weekly for 12 weeks.

      Patients undergo surgery 2-6 weeks after the last chemotherapy dose.

      In all arms, treatment continues in the absence of unacceptable toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in senescence and secondary biomarkers, including TMEM, mena, and 67LR</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Descriptive statistics by treatment group will be presented. The two-sampled t-test will be performed. Appropriate transformation may be used to improved normality of the outcome variable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in quantitative biomarker levels in patients with chemotherapy-responsive and -resistant tumors, including senescence, cell death, TMEM, mena, and 67LR</measure>
    <time_frame>Baseline to 8 weeks (2 courses)</time_frame>
    <description>Paired T-test or Wilcoxon signed-rank test will be performed. Two-sample t-test will be performed to compare biomarker between the two groups. If the data are not normally distributed, a suitable data transformation such as the log or rank transformation will be applied. Logistic regression models will also be fit to the data with treatment sensitive/resistance category as the outcome and baseline as well as pre-post change in biomarker level as the main predictor variable to obtain estimates of odds ratios unadjusted and adjusted for potential confounders including patients characteristics.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Stage IIA Breast Cancer</condition>
  <condition>Stage IIB Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Stratum A (HER2-positive disease)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel IV over 1 hour and trastuzumab IV over 30-90 minutes weekly for 12 weeks. Beginning 2-3 weeks after the last dose of paclitaxel, patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes every 2 weeks for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum B (paclitaxel followed by AC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel, doxorubicin hydrochloride, and cyclophosphamide as in Stratum A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum C (AC followed by paclitaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes every 2 weeks for 8 weeks. Patients then receive paclitaxel IV over 1 hour weekly for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Stratum A (HER2-positive disease)</arm_group_label>
    <arm_group_label>Stratum B (paclitaxel followed by AC)</arm_group_label>
    <arm_group_label>Stratum C (AC followed by paclitaxel)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cytology Specimen Collection Procedure</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Stratum A (HER2-positive disease)</arm_group_label>
    <arm_group_label>Stratum B (paclitaxel followed by AC)</arm_group_label>
    <arm_group_label>Stratum C (AC followed by paclitaxel)</arm_group_label>
    <other_name>Cytologic Sampling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Stratum A (HER2-positive disease)</arm_group_label>
    <arm_group_label>Stratum B (paclitaxel followed by AC)</arm_group_label>
    <arm_group_label>Stratum C (AC followed by paclitaxel)</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Stratum A (HER2-positive disease)</arm_group_label>
    <arm_group_label>Stratum B (paclitaxel followed by AC)</arm_group_label>
    <arm_group_label>Stratum C (AC followed by paclitaxel)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Stratum A (HER2-positive disease)</arm_group_label>
    <arm_group_label>Stratum B (paclitaxel followed by AC)</arm_group_label>
    <arm_group_label>Stratum C (AC followed by paclitaxel)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxol Konzentrat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Stratum A (HER2-positive disease)</arm_group_label>
    <other_name>ABP 980</other_name>
    <other_name>Anti-c-ERB-2</other_name>
    <other_name>Anti-c-erbB2 Monoclonal Antibody</other_name>
    <other_name>Anti-ERB-2</other_name>
    <other_name>Anti-erbB-2</other_name>
    <other_name>Anti-erbB2 Monoclonal Antibody</other_name>
    <other_name>Anti-HER2/c-erbB2 Monoclonal Antibody</other_name>
    <other_name>Anti-p185-HER2</other_name>
    <other_name>c-erb-2 Monoclonal Antibody</other_name>
    <other_name>HER2 Monoclonal Antibody</other_name>
    <other_name>Herceptin</other_name>
    <other_name>Herceptin Biosimilar PF-05280014</other_name>
    <other_name>Herceptin Trastuzumab Biosimilar PF-05280014</other_name>
    <other_name>MoAb HER2</other_name>
    <other_name>Monoclonal Antibody c-erb-2</other_name>
    <other_name>Monoclonal Antibody HER2</other_name>
    <other_name>PF-05280014</other_name>
    <other_name>rhuMAb HER2</other_name>
    <other_name>Trastuzumab Biosimilar ABP 980</other_name>
    <other_name>Trastuzumab Biosimilar PF-05280014</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically confirmed adenocarcinoma of the breast associated
             with the following clinical stage: IIA, IIB, IIIA, IIIB, or IIIC; patients with stage
             IV disease are also eligible if there is an intention to perform breast surgery after
             neoadjuvant therapy is completed, or in patients participating in clinical trials
             where surgery after neoadjuvant therapy may be an option (eg. E2108)

          -  Estrogen receptor (ER), progesterone receptor (PR), and HER2/neu status documented by
             core needle biopsy of the primary tumor and/or regional lymph node must be known prior
             to beginning systemic therapy

          -  Patients must have had a bilateral diagnostic mammogram within 6 months of
             registration, and may also have a targeted sonography of the breast and/or ipsilateral
             axilla and magnetic resonance imaging (MRI) if clinically indicated

          -  Patients with clinically suspicious axillary lymph node involvement must have either
             aspiration cytology or biopsy prior to beginning therapy

          -  It is strongly encouraged that all patients have metallic clips placed in the tumor
             prior to neoadjuvant therapy in order to facilitate evaluation for microscopic disease
             at the time of surgery; placement of clips is particularly encouraged for patients
             being considered for breast conserving surgery

          -  No prior chemotherapy, irradiation, or definitive therapeutic surgery (eg, mastectomy
             or lumpectomy or axillary dissection) for this malignancy; patients who have had a
             prior sentinel lymph node biopsy for this malignancy are eligible

          -  Patients who received tamoxifen or another selective estrogen receptor modulator
             (SERM) for prevention or for other indications (e.g., osteoporosis, prior ductal
             carcinoma in situ [DCIS]) are eligible; tamoxifen therapy or other SERMs should be
             discontinued at least 1 week before the patient is enrolled on this study

          -  The patient is medically suitable candidate for preoperative chemotherapy and surgery
             in the judgment of the treating physicians

          -  Ability to understand and the willingness to sign a written informed consent document,
             and willing to provide blood samples before and during preoperative therapy; patients
             are also asked but not required to have research biopsies performed before and after
             therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Sparano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph A. Sparano</last_name>
      <phone>718-405-8404</phone>
      <email>jsparano@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Joseph A. Sparano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2013</study_first_submitted>
  <study_first_submitted_qc>July 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <last_update_submitted>January 13, 2016</last_update_submitted>
  <last_update_submitted_qc>January 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine, Inc.</investigator_affiliation>
    <investigator_full_name>Joseph Sparano</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

